• Initiated apoptosis and cell cycle arrest in breast and colorectal cancer cells in vitro.• Extended survival in pancreatic, NSCLC, and glioma xenografts in vivo.• Observed anticancer effects in trastuzumab-resistant HER-2+ breast cancer cells. Here, ERBB2 is linked to breast carcinoma.